All of that reflected the lobbying, campaign contributions and indomitable bipartisan power of the pharmaceutical industry in Washington. And it led to a result that this newsletter has been warning about, as Gilead just announced that it will charge privately insured Americans more than $3,000 each for a 5-day COVID treatment that was developed with financial support from the government.
That’s a $3,000 price tag for a government-sponsored drug treatment that experts say the company could offer at $10 and still make a profit.
[links in original omitted].
__________UPDATE___________
This "past week" Google shows the shameful "sweep it under the rug" non-coverage mainstream media gave to the obscene price gouging. It is shameful, but wholly expected that they'd do exactly that.
In fairness, leaving out testimony coverage and making the search more generic, and over the past month - that Google shows, NYT, WSJ, CNN and WaPo do show up on first page of hits. They don't even know if it works, the data is preliminary; the pricing for US in the U.S. is absolute. Strib coverage, local content author listed, not a carry of a nationwide news feed.
Compare: Aljazeera, closing paragraphs:
Gilead has linked up with generic drugmakers based in India and Pakistan, including Cipla Ltd and Hetero Labs Ltd, to make and supply remdesivir in 127 developing countries.
Cipla's version is priced at less than 5,000 Indian rupees ($66.24), while Hetero Lab's version is priced at 5,400 rupees ($71.51).
We get fucked. Image.
